At Home Testing of Neurocognitive Function in People with Alzheimer Disease Shows Potential According to Study from Cumulus Neuroscience
A presentation at the 2023 meeting of the Alzheimer’s Association International Conference (AAIC) demonstrated the potential for at-home sampling of clinical data for patients with early stages of Alzheimer Disease (AD). The study, CNS-101, presented by Cumulus Neuroscience, involves the implementation of the company’s Cumulus Neuroassessment Platform (Cumulus Neuroscience, Belfast, United Kingdom). Interim results demonstrated that patients were willing and able to conduct at-home electroencephalogram (EEG) measurement and behavioral assessment.
CNS-101 is an ongoing study with 119 participants from the United Kingdom, 59 of whom are patients with AD. During the initial 2 weeks of the study, participant took part in 15 30-minute sampling sessions, consisting of behavioral tasks for memory, executive function, affective processing, and language performed with synchronized EEG measurement. Participants with AD presented study protocol compliance rates that were less than 10% lower than those of healthy participants (75% vs 83.3%), and the researchers reported dropout rates of 20% in participants with AD vs 6% in healthy participants. Clinical data collected in the at-home sessions aligned with traditional clinical benchmarks, demonstrating that at-home sampling is feasible and potentially robust.
“This interim analysis has provided confirmation that patients living with Alzheimer's are capable and willing to participate in clinical studies that include at-home EEG, and that our platform is user-friendly and suitable for repeated at-home use,” said Brian Murphy, PhD, Chief Scientific Officer of Cumulus Neuroscience.
Another presentation at the 2023 meeting of the AAIC, by researchers at the Boston University Cobanian & Avedisian School of Medicine, implemented the Cumulus Neuroassessment Platform with wearable monitoring technologies, yielding high adherence and positive results consistent with CNS-101.